Timothy Pardee is Professor at Atrium Health Wake Forest Baptist. OpenAlex indexes 180 publications with 4,871 citations (h-index 34); ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 14 Oct 2026
Overview
Updated 16 Oct 2026
Timothy Pardee, M.D., PH.D., is Professor at Atrium Health Wake Forest Baptist. The public record shows 180 publications with 4,871 citations (h-index 34), centered on Acute Myeloid Leukemia Research, Retinoids in leukemia and cellular processes, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 12 companies, 5 NIH-funded awards (2012–2025).
- Most recent indexed publication: 2025 · Blood advances
- Top research focus: Acute Myeloid Leukemia Research
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 56.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Sponsor: Timothy Pardee
- Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Sponsor: Wake Forest University Health Sciences
- DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: Delta-Fly Pharma, Inc.
Industry payments
Updated 16 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Ipsen InnovationProgram year20254 payments
- Syndax Pharmaceuticals, Inc.Program year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Fluoroquinolone Antibacterial100%Levofloxacin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
5 NIH research awards on record, funded 2012–2025 per NIH RePORTER. The latest:
- Developing Acute Myeloid Leukemia Models with Diverse Ancestral Origins
Wake Forest University Health Sciences
FY2025$177,249R21CA283135 - Translational Oncology Training Program
Wake Forest University Health Sciences
FY2024$266,711T32CA247819 - Developing Acute Myeloid Leukemia Models with Diverse Ancestral Origins
Wake Forest University Health Sciences
FY2024$213,594R21CA283135
Congress activity
Updated 16 Oct 2026
58 congress contributions (2009–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- A randomized phase II study of selinexor added to standard induction and consolidation chemotherapy in adults with acute myeloid leukemia (AML).
ASCO Annual Meeting
ASCO2026Presenting author - Treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using real-world data from a chart review.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.
Blood advances
Clinical Trial2025 - Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia.
Blood advances
Clinical Trial2025 - Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Nature communications
Clinical Trial2022 - Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Leukemia
Clinical Trial2020
Most-cited works
by citation count (OpenAlex)- 01Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AMLArticle1,279 citations2019
- 02
- 03Mouse models of human AML accurately predict chemotherapy responsePreprint279 citations2009
- 04
- 05Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older AdultsArticle140 citations2014
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cms.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cms.gov ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Herrington, MD
Atrium Health Wake Forest Baptist
David Hurd, MD
Atrium Health Wake Forest Baptist
Gordon Lam, MD
Atrium Health Wake Forest Baptist
Bruce Lessey, MD
Atrium Health Wake Forest Baptist
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center